CJC-1295 + Ipamorelin: The Complete Stack Guide

The CJC-1295 and ipamorelin combination is the most widely prescribed growth hormone peptide stack in peptide therapy and performance medicine. The logic behind combining them is straightforward: one amplifies the growth hormone signal, the other makes the pituitary more responsive to it.

But how well does this actually work? And how does it compare to just taking HGH directly?

Let’s walk through what the clinical evidence actually supports.

Key Takeaways

CJC-1295 increases GH and IGF-1 levels for up to 28 days after a single dose — the longest-acting GHRH analog studied in humans [1]
Ipamorelin is the most selective GH secretagogue available — it raises GH without touching cortisol, prolactin, or ACTH, even at 200x the effective dose [2]
The combination targets two separate mechanisms (GHRH + ghrelin receptor), producing a GH pulse that’s larger than either peptide alone
Neither peptide is FDA-approved. CJC-1295 with DAC was discontinued after a death in Phase 2 trials. The no-DAC version and ipamorelin remain research compounds [3]

How the Stack Works: Two Pathways, One Goal
CJC-1295: The GHRH Analog
Ipamorelin: The Selective Secretagogue
Why Combine Them
Dosing Protocols
Benefits: What the Evidence Supports
Side Effects and Safety
CJC-1295/Ipamorelin vs. HGH
FDA Status and Legal Considerations
FAQ
Sources

How the Stack Works: Two Pathways, One Goal

Your pituitary gland releases growth hormone in pulses throughout the day, with the largest pulses during deep sleep. Two signals control this process:

GHRH (Growth Hormone-Releasing Hormone) tells the pituitary to make and release GH. Think of it as pressing the gas pedal. CJC-1295 mimics this signal.

Ghrelin/GHS receptor activation amplifies the pituitary’s response to GHRH and reduces somatostatin (the brake on GH release). Ipamorelin activates this receptor.

When you give both signals at once, the GH pulse is significantly larger than what either signal produces alone. This is called a synergistic effect, and it’s the entire rationale for stacking these two peptides [4][5].

The result mimics — at least partially — the natural pulsatile GH release pattern your body uses. This is different from injecting exogenous HGH, which provides a flat, non-physiological dose.

CJC-1295: The GHRH Analog

CJC-1295 is a synthetic analog of the first 29 amino acids of GHRH, modified to resist enzymatic breakdown. It was developed by ConjuChem Biotechnologies and studied in two forms.

Two Versions: DAC vs. No-DAC

CJC-1295 with DAC includes a Drug Affinity Complex that binds to albumin in the bloodstream. This extends the half-life dramatically — from minutes to about 8 days. A single injection keeps GH and IGF-1 elevated for weeks [1].

CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) lacks the albumin-binding component. Its half-life is about 30 minutes. It produces a sharp GH pulse that more closely mimics natural physiology [1][6].

Most clinical protocols today use the no-DAC version for daily injections. The DAC version is used less frequently after safety concerns arose during trials (more on that below).

The Clinical Data

The key human study was published in the Journal of Clinical Endocrinology & Metabolism in 2006. Researchers gave CJC-1295 with DAC to 21 healthy adults at doses of 30, 60, or 120 mcg/kg via subcutaneous injection [1].

The results were notable:

GH levels increased 2-10 fold depending on dose, with sustained elevation
IGF-1 levels increased 1.5-3 fold and remained elevated above baseline for up to 28 days after a single dose
Mean IGF-1 increased by 36-69% after multiple doses (depending on dose)
The effect was dose-dependent: higher doses produced larger, longer-lasting GH/IGF-1 elevations

At the 30 and 60 mcg/kg doses, the peptide was described as “safe and relatively well tolerated.” The 120 mcg/kg dose showed more side effects [1].

What CJC-1295 Doesn’t Do

CJC-1295 doesn’t create GH out of nothing. It stimulates your pituitary to release more of what it can produce. If your pituitary is damaged or severely age-depleted, the response will be blunted.

It also doesn’t bypass negative feedback. Somatostatin will still kick in and suppress GH release. This is actually why adding ipamorelin (which suppresses somatostatin’s influence) makes the stack work better.

Ipamorelin: The Selective Secretagogue

Ipamorelin is a pentapeptide (five amino acids) that activates the ghrelin/GHS receptor. It was developed by Novo Nordisk in the late 1990s and quickly stood out from other growth hormone secretagogues for one reason: selectivity [2].

Why Selectivity Matters

Older GH secretagogues like GHRP-6 and GHRP-2 stimulated GH release, but they also raised cortisol, prolactin, and ACTH. More cortisol means more fat storage, water retention, and stress on the body. Elevated prolactin can suppress testosterone and cause other hormonal issues.

Ipamorelin breaks this pattern. The original 1998 study — published in the European Journal of Endocrinology — demonstrated that ipamorelin produced dose-dependent GH release in swine without any change in cortisol, prolactin, FSH, LH, TSH, or ACTH. This held true even at doses more than 200 times higher than the effective dose for GH release [2].

That’s a remarkable safety margin. No other GH secretagogue has shown this level of selectivity.

Pharmacokinetics

Ipamorelin has a half-life of about 2 hours when administered intravenously [5]. Subcutaneous injection produces a GH pulse lasting roughly 3 hours. This short duration is actually desirable — it mimics the pulsatile nature of natural GH release.

IV studies showed dose-dependent GH responses, with a clear pharmacokinetic/pharmacodynamic relationship modeled in clinical research [5]. The GH release window is finite — there’s a maximum amount the pituitary will release per pulse, even at very high doses.

Clinical Use Beyond Body Composition

Ipamorelin was studied in a Phase 2 clinical trial for postoperative ileus (gut paralysis after surgery). A 7-day treatment course was generally safe but didn’t significantly improve clinical outcomes for that specific condition [7]. This trial at least confirmed tolerability in hospitalized patients.

Preclinical studies also showed ipamorelin activates the ghrelin receptor in ways that reduce visceral hypersensitivity and may improve bowel function — a secondary benefit some users report [7].

Why Combine Them

The combination works on a basic pharmacological principle: activating two parallel pathways to the same endpoint produces a greater effect than activating either one alone.

The Amplification Effect

When GHRH hits the pituitary, it triggers GH release. But the magnitude of that release depends heavily on how much somatostatin is present (somatostatin suppresses GH). Ghrelin receptor activation by ipamorelin does two things simultaneously:

Directly stimulates GH release through the GHS receptor (a separate mechanism from GHRH)
Reduces somatostatin’s inhibitory tone, making the pituitary more responsive to GHRH [4][5]

The net result: CJC-1295 provides the stimulus, and ipamorelin removes the brake while adding its own push. The GH pulse produced by the combination is larger than the sum of the individual effects [4].

Preserving Natural Rhythm

Unlike exogenous HGH, which delivers a pharmacological bolus that can suppress your own GH production, the CJC-1295/ipamorelin stack works through your pituitary. Your body’s feedback mechanisms remain intact. When GH reaches a certain level, the pituitary stops releasing more.

This preserves the pulsatile release pattern that appears important for GH’s metabolic effects. Some researchers believe that pulsatile GH has different effects on fat metabolism and tissue repair than continuous elevated GH [4][8].

Dosing Protocols

Standard clinical protocols for the CJC-1295 (no-DAC) + ipamorelin stack follow a fairly consistent pattern across anti-aging and peptide therapy clinics.

Standard Protocol

CJC-1295 (no-DAC): 100-300 mcg per injection
Ipamorelin: 100-300 mcg per injection
Frequency: Once daily, subcutaneous injection
Timing: Before bed, ideally 2+ hours after last meal (food — especially carbohydrates and fats — blunts GH release)
Cycle length: 8-16 weeks, with 4-week breaks between cycles [6][9]

Titration Approach

Most providers start conservatively:

Week 1-2: 100 mcg of each peptide, once daily at bedtime
Week 3-4: 200 mcg of each if tolerated well
Week 5+: 200-300 mcg of each, based on response and tolerance

Some protocols add a second daily injection (morning, fasted) for more aggressive GH elevation. This is common in body recomposition programs but increases cost and side effect potential [9].

CJC-1295 with DAC Protocol (Less Common)

For the DAC version, dosing is completely different due to the extended half-life:

Dose: 1-2 mg subcutaneously
Frequency: Once or twice weekly
Clinical trial dose: 30-60 mcg/kg body weight (roughly 2-5 mg for an average adult) [1]

The DAC version produces sustained GH/IGF-1 elevation rather than distinct pulses. Some clinicians prefer the no-DAC version precisely because it preserves pulsatile release.

Injection Technique

Both peptides are reconstituted from lyophilized powder using bacteriostatic water. Injection sites include the lower abdomen, outer thigh, or upper arm. Rotate sites to prevent lipodystrophy. Store reconstituted peptides refrigerated, and use within 4-6 weeks.

Benefits: What the Evidence Supports

Let’s separate what’s backed by clinical data from what’s based on mechanism-of-action reasoning and patient reports.

Strong Evidence (From Clinical Trials)

Increased GH and IGF-1 levels. This is directly demonstrated. CJC-1295 raised IGF-1 by 36-69% in the pivotal human trial [1]. Ipamorelin produced dose-dependent GH pulses in every study it was tested in [2][5].

Moderate Evidence (From GH Research, Not CJC/Ipamorelin Specifically)

Improved body composition. Growth hormone reduces fat mass and increases lean mass. This has been shown repeatedly in GH-deficient adults receiving HGH replacement [8][10]. The assumption is that increasing endogenous GH via peptides produces a similar (though likely smaller) effect. No large RCT has tested this assumption directly with CJC-1295/ipamorelin.

Better sleep quality. GH release is tightly linked to slow-wave sleep. Enhancing GH pulses at night — which bedtime dosing of this stack aims to do — may deepen sleep architecture. Patients frequently report improved sleep within the first 1-2 weeks. Clinical data on sleep specifically is limited to GH replacement studies, not secretagogue studies [8].

Improved recovery from exercise. GH stimulates collagen synthesis, protein synthesis, and tissue repair. Athletes and patients report faster recovery from workouts and injuries. Direct trial data for CJC-1295/ipamorelin and recovery is lacking, but the GH mechanism is well established [10][11].

Anecdotal/Theoretical (Patient Reports, Not Proven)

Better skin quality and hair thickness (GH stimulates collagen)
Increased energy and mental clarity
Improved libido (possibly through better sleep and GH’s effects on overall vitality)
Joint pain reduction (GH stimulates cartilage and synovial fluid)

These are commonly reported in clinical practice but haven’t been tested in controlled studies of this peptide combination.

What You Shouldn’t Expect

This stack is not going to transform your physique like exogenous HGH at pharmacological doses. The GH elevation is real but more modest than injecting 2-4 IU of synthetic HGH daily. Expect gradual improvements in body composition over months, not dramatic changes in weeks.

Side Effects and Safety

Common Side Effects

Most side effects are mild and relate to the GH elevation itself:

Flushing and warmth at injection time (especially with ipamorelin) — usually lasts 15-30 minutes
Headache — reported in about 10-20% of users, typically resolves after the first week
Water retention — mild puffiness, especially in the hands and face. GH increases sodium retention
Tingling or numbness in extremities (paresthesia) — a classic GH-related side effect from fluid shifts
Injection site reactions — redness, itching, or bruising at the injection site
Increased hunger — ipamorelin activates the ghrelin receptor, which stimulates appetite [2][7]
Dizziness or lightheadedness — occasionally reported, usually transient

Serious Concerns

CJC-1295 with DAC and the clinical trial death. During Phase 2 clinical trials of CJC-1295 with DAC for lipodystrophy and GH deficiency, one participant died. The program was subsequently discontinued [3]. The exact cause and its relationship to the peptide aren’t fully public. This is specifically about the DAC version — the no-DAC formulation (Mod GRF 1-29) has a different pharmacokinetic profile and has not been associated with similar events.

Chronic IGF-1 elevation. Long-term elevation of IGF-1 is associated with increased cancer risk in epidemiological studies. If you’re using GH peptides over months or years, periodic IGF-1 blood monitoring is advisable. This is the main reason for cycling on and off rather than continuous use [8][12].

Pituitary desensitization. Theoretical concern with long-term use of any secretagogue. Continuous stimulation could downregulate receptor sensitivity. Cycling (8-16 weeks on, 4 weeks off) is intended to prevent this, though the evidence for desensitization specifically with these peptides is limited [4].

Who Should Avoid This Stack

Individuals with active cancer or a history of cancer (GH/IGF-1 may promote tumor growth)
Pregnant or breastfeeding women
People with uncontrolled diabetes (GH can worsen insulin resistance)
Anyone with active pituitary disease
People under 25 (growth plates may still be open in some individuals)

CJC-1295/Ipamorelin vs. HGH

This is the comparison everyone wants to know about. Here’s a straightforward breakdown.

Exogenous HGH

Mechanism: You inject synthetic growth hormone directly. Bypasses the pituitary entirely.
GH elevation: Precise and predictable. You control exactly how much GH enters your body.
Typical dose: 1-3 IU/day for anti-aging; 4-8 IU/day for performance (higher doses carry more risk)
Cost: $500-$1,500+/month for pharmaceutical-grade HGH
FDA status: Approved for GH deficiency, Turner syndrome, and a few other conditions. Off-label use for anti-aging is common but legally gray.
Downsides: Suppresses natural GH production. Non-pulsatile delivery. Potential for insulin resistance, carpal tunnel, joint pain, and edema at higher doses. Requires careful dosing [8][10].

CJC-1295 + Ipamorelin Stack

Mechanism: Stimulates your own pituitary to produce and release more GH. Works through natural feedback systems.
GH elevation: Variable depending on your pituitary health and age. Generally more modest than pharmacological HGH doses.
Typical dose: 200-300 mcg each, once daily
Cost: $150-$400/month from compounding pharmacies
FDA status: Not approved for any indication
Advantages: Preserves pulsatile release pattern. Less likely to cause insulin resistance at standard doses. Maintains negative feedback (harder to “overdose”). Lower cost. Cleaner side effect profile at typical doses [1][2][4].

The Honest Comparison

HGH is more powerful. If you have diagnosed GH deficiency and need significant hormone replacement, the peptide stack is an inferior substitute for pharmaceutical HGH under medical supervision.

But for adults with normal-to-low GH levels who want to optimize body composition, sleep, and recovery, the CJC-1295/ipamorelin stack offers a more physiological approach with fewer side effects and lower cost. Many clinicians see it as a first-line option before considering HGH. For more on how GH peptides fit into the broader peptide therapy landscape, see our overview guide.

The stack also has a practical advantage: it’s harder to overshoot. Your pituitary has a ceiling on how much GH it can release per pulse. With exogenous HGH, there’s no such safeguard.

FDA Status and Legal Considerations

Neither CJC-1295 nor ipamorelin is FDA-approved for any medical condition.

CJC-1295 with DAC reached Phase 2 clinical trials but was discontinued [3]. Ipamorelin completed a Phase 2 trial for postoperative ileus but didn’t show efficacy for that indication and wasn’t pursued further [7].

In the United States, these peptides have been available through compounding pharmacies under the 503A and 503B exemptions of the Federal Food, Drug, and Cosmetic Act. However, the FDA has been actively reviewing which bulk drug substances can be used in compounding, and the regulatory landscape for peptides has shifted significantly since 2023.

As of early 2026, both CJC-1295 and ipamorelin remain under FDA review for inclusion on the bulk drug substances list for compounding. Availability may change. Check with your provider for current status.

Tesamorelin — a related GHRH analog — is the only peptide in this class with full FDA approval (for HIV lipodystrophy). Some clinicians use tesamorelin as an FDA-approved alternative to CJC-1295 for patients who prefer a regulated option.

FAQ

How long does it take for CJC-1295/ipamorelin to work?▼

GH and IGF-1 levels begin rising within hours of the first injection. Most patients notice improved sleep quality within 1-2 weeks. Body composition changes (reduced body fat, improved muscle tone) typically become apparent at 8-12 weeks with consistent use and exercise [1][9]. Don’t expect overnight results — this is a slow-build approach.

Can I take CJC-1295 and ipamorelin together in one injection?▼

Yes. Most compounding pharmacies supply them as a pre-mixed blend in a single vial, and single-injection administration is standard practice. Mixing them doesn’t reduce efficacy. In fact, simultaneous delivery may produce a stronger GH pulse since both pathways are activated at the same time [4][6].

What time of day should I inject CJC-1295/ipamorelin?▼

Before bed, at least 2 hours after eating. Growth hormone release is naturally highest during deep sleep, and injecting at bedtime aligns the peptide-stimulated pulse with your body’s circadian rhythm. Food — particularly carbs and fats — triggers insulin release, which blunts GH secretion. An empty stomach is important for maximum effect [6][9].

Will CJC-1295/ipamorelin show up on a drug test?▼

Standard workplace drug panels (5 or 10 panel) do not test for peptides. However, the World Anti-Doping Agency (WADA) and most professional sports organizations ban growth hormone secretagogues. If you’re a competitive athlete subject to WADA testing, these peptides are prohibited both in-competition and out-of-competition.

Is the CJC-1295/ipamorelin stack safe long-term?▼

The short answer: we don’t have long-term safety data. The longest clinical trial of CJC-1295 ran for several weeks [1]. There are no multi-year studies on either peptide. The main theoretical risk of long-term use is chronic IGF-1 elevation and its association with cancer risk. Cycling (on/off periods) and periodic blood work monitoring IGF-1 levels are considered best practices. Ipamorelin’s selectivity profile — no cortisol or prolactin elevation — is reassuring for the hormonal side effect picture [2][12].

Sources

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhatt R. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed: 16352683
Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed: 9849822
CJC-1295. Wikipedia. Accessed March 2026. en.wikipedia.org/wiki/CJC-1295
Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. doi:10.1002/rco2.9
Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159.
FDA Nomination Document: CJC-1295 Modified GRF (1-29) and CJC-1295 + DAC. FDA Docket FDA-2024-N-4777. regulations.gov
Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Preprints.org. 2025. doi:10.20944/preprints202512.1011.v1
Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMC5632578
Clinical dosing protocols. Alpha Rejuvenation; Peptide Dosages. Accessed March 2026. alpha-rejuvenation.com
Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323(1):1-6. (Landmark GH replacement study)
FDA Nomination Document: Ipamorelin bulk drug substance. FDA Docket FDA-2024-N-4188. regulations.gov
Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353.